Nuojua-Huttunen S, Tomas C, Bloigu R, Tuomivaara L, Martikainen H. Intrauterine insemination treatment in subfertility: an analysis of factors affecting outcome. Hum Reprod. 1999;14(3):698–703 (0268–1161).PubMedCrossRef

Guzick DS, Carson SA, Coutifaris C, Overstreet JW, Factor-Litvak P, Steinkampf MP, Hill JA, Mastroianni L, Buster JE, Nakajima ST, Vogel DL, Canfield RE. Efficacy of superovulation and intrauterine insemination in the treatment of infertility. National Cooperative Reproductive Medicine Network. N Engl J Med. 1999 Jan 21;340(3):177–83.PubMedCrossRef

Veltman-Verhulst SM, Cohlen BJ, Hughes E, Heineman MJ. Intra-uterine insemination for unexplained subfertility. Cochrane Database Syst Rev. 2012;9: CD001838. doi:10.1002/14651858.CD001838.pub4.PubMed

Karlström PO, Bergh T, Lundkvist O. A prospective randomized trial of artificial insemination versus intercourse in cycles stimulated with human menopausal gonadotropin or clomiphene citrate. Fertil Steril. 1993 Mar;59(3):554–9.PubMed

Costello MF. Systematic review of the treatment of ovulatory infertility with clomiphene citrate and intrauterine insemination. Aust N Z J Obstet Gynaecol. 2004 Apr;44(2):93–102 (0004–8666).PubMedCrossRef

Steures P, van der Steeg JW, Hompes PG, Habbema JD, Eijkemans MJ, Broekmans FJ, Verhoeve HR, Bossuyt PM, van der Veen F, Mol BW, Collaborative Effort on the Clinical Evaluation in Reproductive Medicine. Intrauterine insemination with controlled ovarian hyperstimulation versus expectant management for couples with unexplained subfertility and an intermediate prognosis: a randomised clinical trial. Lancet. 2006 Jul;368(9531):216–21.PubMedCrossRef

Brandes M, Hamilton CJ, van der Steen JO, de Bruin JP, Bots RS, Nelen WL, Kremer JA. Unexplained infertility: overall ongoing pregnancy rate and mode of conception. Hum Reprod. 2011;26(2):360–68.PubMedCrossRef

NICE Guideline. Fertility: assessment and treatment for people with fertility problems. NICE clinical guideline (CG 156). 2013;1.8.1: 3–4

Nadeem R. Unexplained infertility: an exploration of women’s perceptions of diagnosis, treatment and decision-making. J Obstet Gynaecol. 2010 Jan;30(1):83–84 (0144–3615).

Gemzell CA, Diczfalusy E, Tillinger KG. Clinical effects of human pituitary follicle stimulating hormone (FSH). J Clin Endocrinol Metab. 1958;18:138–48.

European and Israeli Study group on highly purified Menotropin versus Recombinant Follicle Stimulating Hormone. Efficacy and safety of highly purified menotropin versus recombinant follicle-stimulating hormone in in vitro fertilization/intracytoplasmic sperm injection cycles: a randomised. Comparative trial. Fertil Steril. 2002;78(3):520–8.CrossRef

Anderson AN, Devroey P, Arce JC. Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing IVF: a randomised assessor- blind controlled trial. Hum Reprod. 2006;21(12):3217–27.CrossRef

Coomarasamy A, Afnan M, Cheema D, van der Veen F, Bossuyt PM, van Wely M. Urinary hMG versus recombinant FSH for controlled ovarian hyperstimulation following an agonist long down-regulation protocol in IVF or ICSI treatment: a systematic review and meta-analysis. Hum Reprod. 2008;23(2):310–5.PubMedCrossRef

Trew GH, Brown AP, Gillard S, Blackmore S, Clewlow C, O’’Donohoe P, Wasiak R. In vitro fertilisation with recombinant follicle stimulating hormone requires less IU usage compared with highly purified human menopausal gonadotrophin: results from a European retrospective observational chart review. Reprod Biol Endocrinol. 2010;8:(137). doi:10.1186/1477-7827-8-137 (1477–7827).

Demirol A, Gurgan T. Comparison of different gonadotrophin preparations in intrauterine insemination cycles for the treatment of unexplained infertility: a prospective randomized study. Hum Reprod. 2007 Jan;22(1):97–100 (Epub 2006 Sep 5).PubMedCrossRef

Ravelli A, Poso F, Gennarelli G, Moffa F, Grassi G, Massobrio M. Recombinant versus highly-purified, urinary follicle stimulating hormone (r-FSH vs HP-uFSH) in ovulation induction: a prospective, randomized study with cost-minimization analysis. Reprod Biol Endocrinol. 2006 Jul;4:38.CrossRef

Van Wely M, Kwan I, Burt AL, et al. Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles. Cochrane Database Syst Rev. 2011;2:CD005354.PubMed

Brown JB. Pituitary control of ovarian function–concepts derived from gonadotrophin therapy. Aust N Z J Obstet Gynecol. 1978 Feb;18(1):46–54.CrossRef

Scheele F, Schoemaker J. The role of follicle-stimulating hormone in the selection of follicles in human ovaries: a survey of the literature and a proposed model. Gynaecol Endocrinol. 1996;10:55–66.CrossRef

Fauser BC, Van Heusden AM. Manipulation of human ovary function: physiological concepts and clinical consequences. Endocr Rev. 1997;18:71–106.PubMed

Practice Committee of the American Society for Reproductive Medicine. Effectiveness and treatment for unexplained infertility. Fertil Steril. 2006;86:S111–4.

Pittman JH, Hammoud A, Keye WR, Gurtcheff SE, Czajkowski L, Gibson M. Psychological and physical symptoms in women undergoing superovulation with clomiphene citrate: a double-blind, placebo-controlled, crossover study. Fertil Steril. 2011 Sept;96(3):S153 (0015–0282).CrossRef

Dankert T, Kremer JA, Cohlen BJ, Hamilton CJ, Pasker-de Jong PC, Straatman H, van Dop PA. A randomized clinical trial of clomiphene citrate versus low dose recombinant FSH foe ovarian hyperstimulation in intrauterine insemination cycles for unexplained and male subfertility. Hum Reprod. 2007 Mar;22(3):792–7 (Epub 2006 Nov 16).PubMedCrossRef

Berker B, Kahraman K, Taskin S, Sukur YE, Sonmezer M, Atabekoglu CS. Recombinant FSH versus clomiphene citrate for ovarian stimulation in couples with unexplained infertility and male subfertility undergoing intrauterine insemination: a randomized trial. Arch Gynecol Obstet. 2011 Dec;284(6):1561–6 (0932–0067;1432–0711).PubMedCrossRef